Value
7.6/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 5.6 |
| Analyst target | 9.0 |
- ▸Attractively valued
VSTM · Why this verdict
Why Verastem (VSTM) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.6/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Verastem pairs a perfect 4-quarter earnings beat streak and positive insider signals with real technical risk, an RSI of 92 inside a still-confirmed downtrend and 28% short interest the engine calls justified, leaving the position at zero conviction ahead of an earnings catalyst in 19 days.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Verastem has beaten estimates in all 4 of its last 4 quarters by an average surprise of 21.85%, and the engine flags earnings in 19 days as a specific catalyst tied to that streak. Earnings | The beat streak should extend to at least 5 of the next 6 quarters, keeping the average surprise positive, over the next 12 months. | ↓Deteriorating |
| CounterBinary biotech earnings events carry outsized event risk, and a single disappointing readout could break the streak regardless of past performance. | ||
Positive insider activity is cited directly as a bull-case factor supporting the stock, alongside institutional accumulation noted in the insider scoring. Bull case | Insider and institutional positioning should stay net positive, with continued accumulation rather than distribution, over the next 12 months. | ↑Improving |
| CounterRecent Form-4 filings show a net sale of 25,766 shares over the past 90 days, producing a bearish insider signal that could offset the bull case if selling accelerates. | ||
RSI sits at an extreme 92, which the momentum notes characterize as an overbought bear rally within a confirmed downtrend, even though the recovering momentum score cleared the death-cross warning threshold. Momentum breakdown | RSI should cool from 92 toward a more sustainable 50-70 range without a sharp price reversal, over the following weeks. | ↓Deteriorating |
| CounterAn RSI of 92 inside a stock still below its 200-day moving average is a classic setup for a sharp pullback rather than a continuation of the rally. | ||
Short interest stands at 28%, and the risk scoring notes explicitly this elevated short interest is justified rather than a setup for a squeeze. Risk breakdown | Short interest should decline from 28% only if the earnings catalyst and beat streak materially de-risk the bear thesis over the next 12 months. | ↓Deteriorating |
| CounterA 28% short interest against a stock with a 4-quarter beat streak and a recovering momentum score is also the classic profile for a short squeeze if the next earnings print beats again. | ||
Free cash flow is burning at -187% of revenue, an extreme rate that anchors the quality concerns despite the strong catalyst and momentum backdrop. Quality breakdown | The free cash flow burn rate should narrow from -187% of revenue as the company progresses toward commercialization over the next 12 months. | Tripped↑Improving |
| CounterExtreme cash burn relative to a small revenue base is typical for a clinical-stage biotech and does not necessarily indicate near-term financial distress if cash runway is sufficient. | ||
Verastem has beaten estimates in all 4 of its last 4 quarters by an average surprise of 21.85%, and the engine flags earnings in 19 days as a specific catalyst tied to that streak.
↓DeterioratingEarnings
- Expectation
- The beat streak should extend to at least 5 of the next 6 quarters, keeping the average surprise positive, over the next 12 months.
CounterBinary biotech earnings events carry outsized event risk, and a single disappointing readout could break the streak regardless of past performance.
Positive insider activity is cited directly as a bull-case factor supporting the stock, alongside institutional accumulation noted in the insider scoring.
↑ImprovingBull case
- Expectation
- Insider and institutional positioning should stay net positive, with continued accumulation rather than distribution, over the next 12 months.
CounterRecent Form-4 filings show a net sale of 25,766 shares over the past 90 days, producing a bearish insider signal that could offset the bull case if selling accelerates.
RSI sits at an extreme 92, which the momentum notes characterize as an overbought bear rally within a confirmed downtrend, even though the recovering momentum score cleared the death-cross warning threshold.
↓DeterioratingMomentum breakdown
- Expectation
- RSI should cool from 92 toward a more sustainable 50-70 range without a sharp price reversal, over the following weeks.
CounterAn RSI of 92 inside a stock still below its 200-day moving average is a classic setup for a sharp pullback rather than a continuation of the rally.
Short interest stands at 28%, and the risk scoring notes explicitly this elevated short interest is justified rather than a setup for a squeeze.
↓DeterioratingRisk breakdown
- Expectation
- Short interest should decline from 28% only if the earnings catalyst and beat streak materially de-risk the bear thesis over the next 12 months.
CounterA 28% short interest against a stock with a 4-quarter beat streak and a recovering momentum score is also the classic profile for a short squeeze if the next earnings print beats again.
Free cash flow is burning at -187% of revenue, an extreme rate that anchors the quality concerns despite the strong catalyst and momentum backdrop.
Tripped↑ImprovingQuality breakdown
- Expectation
- The free cash flow burn rate should narrow from -187% of revenue as the company progresses toward commercialization over the next 12 months.
CounterExtreme cash burn relative to a small revenue base is typical for a clinical-stage biotech and does not necessarily indicate near-term financial distress if cash runway is sufficient.
Per-dimension breakdown
Quality
4.7/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Current ratio | 7.8 |
| FCF quality | 0.0 |
| Moat | 5.8 |
| Rule of 40 | 9.5 |
| Piotroski F | 4.4 |
- ▸Cash-burning: FCF -118% of revenue
- ▸Rule of 40: 1657 (elite)
Growth
5.0/10data confidence 50%Momentum
4.2/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 6.7 |
| OBV | 1.0 |
| MA position | 8.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-MA but MA slope flat
Sentiment
8.5/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.8 |
| Analyst rating | 7.9 |
| Price target | 10.0 |
- ▸LLM news sentiment: +0.55 (n=1)
- ▸Light analyst coverage (8.0) — signal dampened
- ▸Analyst upside: 118%
Insider
7.3/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Insider selling (low materiality) — $111,895 (0.019% of mkt cap)
- ▸Institutions accumulating
Peer rank
4.2/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 6.2 |
| quality rank | 0.0 |
| growth rank | 10.0 |
- ▸Industry growth leader
Technical
2.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 2.1 |
| support resistance | 2.5 |
| 52w position | 2.0 |
Risk (lower is worse)
2.8/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 1.3 |
| days to cover | 2.5 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| max pain risk | 5.0 |
| beta | 10.0 |
| debt equity | 3.6 |
- ▸High short interest justified: 22%
- ▸Elevated put/call: 35.71
- ▸High IV: 115%
- ▸Concentration risks: 1 HIGH, 1 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 9.6 |
| news activity | 5.0 |
- ▸Perfect beat streak: 4Q
How the verdict was assembled
Engine trigger
Extreme risk factors.
Engine technical detail
verdict_path:
L1:HARD_BLOCK:RISK_FLOORPassed (7)
- ASYMMETRY:6.0>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:78d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:4.2<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (0)
none
Reward-to-Risk
5.98
Upside
+89.7%
Downside
15.0%
Sizing output
AVOID
SetupMomentum Cont — Trend continuation, RSI 60, MACD bullish
EdgeInst Constrain — Small cap ($0.6B) below institutional reach
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The SELL_IF_HOLDING verdict reflects the MOMENTUM gate's 4.2<4.5 outcome against Sentiment at 8.5 and asymmetric R:R of 5.98.
The strongest dimensions are Sentiment at 8.5, Value at 7.6, and Insider at 7.3; the weakest are Technical at 2.2, Risk (lower is worse) at 2.8, and Peer rank at 4.2. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 5.98 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Perfect Earnings Beat Streak Catalyst
Trip ifThe company misses earnings in at least 2 of the next 4 quarters, breaking the current 4-of-4 beat streak.
- P2Positive Insider Activity Bull Case
Trip ifNet insider selling exceeds 100,000 shares over the next 90 days, extending well beyond the current -25,766 share signal.
- P3Overbought Bear Rally Risk
Trip ifRSI stays above 80 for more than 20 consecutive trading days without a pullback, confirming an unsustainable overbought extension rather than a cooling rally.
- P4Justified High Short Interest
Trip ifShort interest rises above 35% from the current 28%, without a corresponding earnings beat to justify continued bearish positioning.
- P5Severe Cash BurnTripped
Trip ifFree cash flow drops below -250% of revenue, deepening from the current -187% burn rate.